Kura Oncology (KURA) Non-Current Deffered Revenue (2024 - 2026)

Kura Oncology (KURA) has 3 years of Non-Current Deffered Revenue data on file, last reported at $416.7 million in Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $416.7 million, up 53.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $416.7 million (up 53.26% YoY), and the FY2025 annual result was $424.9 million, up 67.35% from the prior year.
• Non-Current Deffered Revenue retreated to $416.7 million in Q1 2026 per KURA's latest filing, from $424.9 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $424.9 million in Q4 2025 and troughed at $252.5 million in Q2 2025.
• A 3-year average of $314.8 million and a median of $270.4 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2025 and 2026: Non-Current Deffered Revenue surged 67.35% in 2025, then jumped 53.26% in 2026.
• A 3-year view of Non-Current Deffered Revenue shows it stood at $253.9 million in 2024, then surged by 67.35% to $424.9 million in 2025, then decreased by 1.92% to $416.7 million in 2026.
• Business Quant data shows KURA's Non-Current Deffered Revenue at $416.7 million in Q1 2026, $424.9 million in Q4 2025, and $268.9 million in Q3 2025.